title: Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?
authors.forename: R
authors.initials: R
authors.lastname: Balestri
authors.forename: F
authors.initials: F
authors.lastname: Bardazzi
authors.forename: A
authors.initials: A
authors.lastname: Antonucci
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D056687:Off-Label Use; D010916:Pityriasis Rubra Pilaris / Q000188:drug therapy*; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D000069549:Ustekinumab